mirikizumab   Click here for help

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Approved drug Immunopharmacology Ligand
mirikizumab is an approved drug (Japan, EMA and FDA (2023))
Compound class: Antibody
Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].
No information available.
Summary of Clinical Use Click here for help
Mirikizumab (LY3074828) was advanced to Phase 3 evaluation in autoimmune conditions, including psoriasis, ulcerative colitis, Crohn's disease. It was granted first approval in Japan in 2023, as an induction and maintenance treatment for ulcerative colitis [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02891226 A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease Phase 2 Interventional Eli Lilly and Company
NCT02899988 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis Phase 2 Interventional Eli Lilly and Company
NCT02589665 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis Phase 2 Interventional Eli Lilly and Company 4
NCT03535194 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Phase 3 Interventional Eli Lilly and Company This study is comparing mirikizumab with Novartis' psoriasis anti-IL-17A drug secukinumab (and both biologics vs. placebo) in patients with moderate-severe psoriasis.